Strides Arcolab has received United States Food and Drug Administration (USFDA) approval for Polymyxin B for injection, USP, an antibacterial drug, in 500,000 unit per vial, latex free glass vials. The product is expected to be launched in Q3 2011.
Polymyxin B sulfate is an antibacterial drug used in the treatment if infections of the urinary tract, meninages and bloodstreams caused by susceptible strains of Pseudomonas aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Pseudomonas aeruginosa.
Strides Arcolab is a global pharmaceuticals company headquartered in Banglore, India that develops and manufactures wide range of IP-led niche pharmaceuticals products with an emphasis on sterlite injectables.
